Mihály Hajós

TL;DR: Systemic administration of PNU-120596 to rats improved the auditory gating deficit caused by amphetamine, a model proposed to reflect a circuit level disturbance associated with schizophrenia, and has the potential to treat psychiatric and neurological disorders.

TL;DR: Pretreatment with the selective 5‐HT1A receptor antagonist, WAY 100635, blocked the inhibitory effect of paroxetine on5‐HT neuronal activity in the DRN and, at the same time, markedly enhanced the effect ofParoxetines on extracellular 5‐ HT in the FCx.

TL;DR: Electrophysiological and pathway tracing methods show that stimulation of the ventral medial prefrontal cortex causes a marked post-stimulus inhibition in the vast majority of midbrain raphe 5-hydroxytryptamine neurons tested, and it seems likely that the projection from ventral lateral prefrontal cortex to the mid brain raphe nuclei mediates the responses of 5-Hydroxytiptamine neurons to cortical stimulation.

TL;DR: Recent advances in neurophysiological techniques provide new opportunities to measure abnormal brain functions in patients with schizophrenia and to compare these with drug-induced alterations, offering unique opportunities for use as translational biomarkers in schizophrenia drug discovery.

TL;DR: The discovery of a new class of PDE10A inhibitors exemplified by TP-10 (2-{4-[-pyridin-4-yl-1-(2,2-trifluoro-ethyl)-1H-pyrazol-3-yl]-phenoxymethyl}-quinoline succinic acid), an agent with greatly improved potency, selectivity, and pharmaceutical properties is described.